NOV 08, 2017
Bevacizumab in ROP
Pediatric Ophthalmology Subspecialty Day 2016
03:03
Pediatric Ophth/Strabismus, Vitreoretinal Diseases
In this presenation from Pediatric Subspecialty Day 2016, Dr. Janice Law makes the case that there are clinical advantages to using bevacizumab including the larger molecule more easily staying in the eye and a longer half-life, which prolongs its effect.